Health 28 January 2026 - 24 February 2026

Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan
···

Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan

Eli Lilly shares fell 1.6% to $1,042.15 Tuesday, then edged up 0.1% after hours, following FDA clearance of a four-dose Zepbound KwikPen for weight loss. The new device will cost $299 per month for cash customers. Novo Nordisk announced it will cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027. Investors weighed pricing moves and clinical trial results as competition intensified.
February 25, 2026
Eli Lilly stock price slips as Novo Nordisk signals Ozempic, Wegovy list-price cuts
···

Eli Lilly stock price slips as Novo Nordisk signals Ozempic, Wegovy list-price cuts

Eli Lilly shares fell 1.3% to $1,045.05 after Novo Nordisk said it will cut U.S. list prices for Ozempic and Wegovy to $675 a month starting January 2027. The move shifts investor focus to drug pricing and margins, despite Lilly’s recent clinical win over Novo’s CagriSema. Barclays slashed its peak sales forecast for CagriSema to $2 billion from $12 billion after new trial data.
February 24, 2026
Eli Lilly stock jumps as Novo’s obesity-drug trial stumbles — what traders watch next
···

Eli Lilly stock jumps as Novo’s obesity-drug trial stumbles — what traders watch next

Eli Lilly shares jumped 4% to $1,049.85 Monday after Novo Nordisk reported its obesity drug CagriSema trailed Lilly’s Zepbound in a head-to-head trial. Novo said CagriSema cut body weight by 23% over 84 weeks, compared to 25.5% for Zepbound. The FDA also cleared a new four-dose Zepbound pen for self-pay patients. Broader U.S. markets fell amid tariff concerns.
February 23, 2026
Pfizer stock slips in premarket as tariff jitters hit futures and weight-loss race resurfaces
···

Pfizer stock slips in premarket as tariff jitters hit futures and weight-loss race resurfaces

Pfizer shares fell 0.7% to $26.65 in premarket trading Monday, following a broader decline in U.S. stock futures after President Donald Trump announced a new 15% tariff. Eli Lilly stock rose after Novo Nordisk’s obesity drug CagriSema underperformed in a head-to-head trial. Pfizer is advancing its own obesity drug, PF’3944, with Phase 3 trials expected in 2026.
February 23, 2026
Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
···

Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise

Grail shares fell about 50% to $50.21 in after-hours trading after its Galleri cancer blood test missed the main goal in a major UK trial. The study failed to show a statistically significant drop in late-stage cancers. Grail said it will release fuller data later this spring and extend trial follow-up. Investors are watching for U.S. regulatory and Medicare decisions.
February 20, 2026
Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test
···

Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test

Grail shares plunged 49.5% to $51.26 by midday Friday after its NHS-Galleri trial missed the primary endpoint of reducing stage III-IV cancers. The company said it would extend follow-up and submit results to ASCO. Over 10 million shares traded. Galleri’s FDA approval process continues, but analysts flagged uncertainty over insurance coverage.
February 20, 2026
Herbalife stock price today: HLF slips premarket after 18% surge on earnings, Ronaldo Pro2col stake
···

Herbalife stock price today: HLF slips premarket after 18% surge on earnings, Ronaldo Pro2col stake

Herbalife shares fell 0.6% to $19.46 premarket Friday after surging 18.3% to a 52-week high in the prior session. The company forecast 2026 net sales growth of 1%–6% and adjusted EBITDA of $670–$710 million. Cristiano Ronaldo invested $7.5 million for a 10% stake in Pro2col Software. China and North America sales declined in the fourth quarter.
February 20, 2026
Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer
···

Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer

Merck shares closed down 0.03% at $119.28 after the FDA approved a Keytruda-based regimen for certain platinum-resistant ovarian cancer patients. The stock had reached $121.62 earlier in the session. Merck also announced new bladder and kidney cancer data to be presented at ASCO GU later this month. Chief Marketing Officer Chirfi Guindo sold 10,000 shares at an average price of $121.46.
February 12, 2026
Namibia wants $94 million to keep foot-and-mouth disease out as China hands over satellite data station
···

Namibia wants $94 million to keep foot-and-mouth disease out as China hands over satellite data station

Namibia’s agriculture minister said the country needs N$1.5 billion ($94 million) more to guard its livestock industry against foot-and-mouth disease as outbreaks in South Africa and Botswana move closer. Cabinet has approved N$57.5 million, but officials warn exports could halt if the virus crosses the border. Namibia also received its first China-backed satellite data station for agriculture and related sectors.
February 12, 2026
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus
···

Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus

Viking Therapeutics shares fell 0.7% to $28.55 in premarket trading Thursday after outlining plans to advance its oral obesity drug VK2735 into Phase 3 trials in the third quarter of 2026. The company completed enrollment for a Phase 3 injectable VK2735 study and reported a fourth-quarter net loss of $157.7 million, ending 2025 with $706 million in cash and equivalents.
February 12, 2026
Novo Nordisk’s CagriSema tops Wegovy in new diabetes trial — 14.2% weight loss at top dose
··

Novo Nordisk’s CagriSema tops Wegovy in new diabetes trial — 14.2% weight loss at top dose

Novo Nordisk said its experimental CagriSema injection led to 14.2% weight loss over 68 weeks in adults with type 2 diabetes, outperforming Wegovy’s 10.2%. HbA1c fell by 1.91 percentage points with CagriSema, compared to 1.76 with semaglutide alone. The company plans to seek regulatory approval for CagriSema in type 2 diabetes. Most side effects were gastrointestinal and mild to moderate.
February 2, 2026
New blood test markers may spot pancreatic cancer earlier — and beat CA19-9 alone
·

New blood test markers may spot pancreatic cancer earlier — and beat CA19-9 alone

A four-protein blood test detected 91.9% of pancreatic cancers and 87.5% of early-stage cases in stored samples, with a 5% false-positive rate, NIH researchers reported Friday. The panel combined two newly identified proteins with CA19-9 and THBS2. Researchers said larger, prospective studies are needed before clinical use. Routine screening for pancreatic cancer remains unrecommended for average-risk adults.
January 30, 2026
US threatens to hold back Gavi cash unless it drops mercury preservative thimerosal
···

US threatens to hold back Gavi cash unless it drops mercury preservative thimerosal

The U.S. is withholding a $300 million pledge to Gavi unless the group starts phasing out thimerosal-containing vaccines, officials said. Gavi confirmed the request but said changes require board approval and must align with scientific consensus. Experts warn a rapid shift from multi-dose vials could raise costs and disrupt immunization efforts in low-income countries.
January 29, 2026
1 2 3